Centre National De La Recherche Scientifique

Institut Pasteur

Institut National De La Sante Et De La Recherche Medicale

Biomerieux, Inc.

Institut Curie

Other

Monique Arpin

Daniel Louvard

Alphonse Garcia

Eric Pringault

Jean-Philippe Charrier

Genevieve Choquet-Kastylevsky

Sylvie Robine

Corinne Beaulieu

Brigitte Dudouet

Sandrine Busseret

Dominique Rolland

Nicole Battail-Poirot

Tiziana Crepaldi

Geneviève Choquet-Kastylevsky

Yasemin Ataman-Önal

Yasmin Ataman-Onal

Alexis Gautreau

Yasemin Ataman-Oenal

A method for the in vitro diagnosis of colorectal cancer by determining the presence of the I-Plastin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.

I-Plastin assay method for the in vitro diagnosis of colorectal cancer

A method for the in vitro diagnosis of colorectal cancer by determining the presence of the Ezrin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer using at least one anti-Ezrin monoclonal antibody directed against an Ezrin epitope chosen from the epitopes of sequence SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4+SEQ ID No. 5, SEQ ID No. 6+SEQ ID No. 7 and SEQ ID No. 8. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.

Ezrin assay method for the in vitro diagnosis of colorectal cancer

The invention relates to a pharmaceutical composition containing an effective amount of ezrin mutated on tyrosine 353, or a functional fragment or derivative thereof, in association with a pharmaceutically acceptable carrier, for use preferably in the prevention and/or treatment of tumors.

Pharmaceutical composition containing ezrin mutated on tyrosine 353

The invention relates to nucleic acid fragments characterized in that they comprise from 8 to 40 nucleotides and in that their sequence is contained either in the DNA coding sequence of the gene for human villin or in any DNA fragment exactly complementary to one of the former and hence containing the same number of deoxynucleotides, or any corresponding RNA fragment containing the same number of ribonucleotides. The invention also relates to the application of these fragments to a procedure for the in vitro detection of the presence of a nucleic acid characteristic of human villin.

Specific nucleic acid fragments of the gene for human villin-their use

Antibodies, both polyclonal and monoclonal, recognize and bind human villin. Hybridomas, producing monoclonal antibodies which bind human villin, are also provided.

Antibodies which recognize and bind human villin

In vitro diagnosis of malignant cells originating in the digestive tract by placing a biological specimen in contact with a reagent recognizing the gene coding for human villin.

Agents for the in vitro diagnosis of malignant cells originating in the

Growing community of inventors

Paris, France

Monique Arpin